I
Intercytex
Biotechnology company developing cell-based therapies for the repair and regeneration of skin and hair
About Intercytex
Intercytex Ltd. is a pioneering regenerative medicine company based in the United Kingdom, focused on developing innovative, cell-based therapies that restore and regenerate human tissues, founded in 2000, the company has positioned itself at the forefront of skin and hair regeneration, leveraging the power of living human cells to address critical unmet medical needs in dermatology and aesthetic medicine, its flagship product, ICX-RHY, is a human dermal fibroblast therapy designed to treat conditions such as epidermolysis bullosa, burn scars, and age-related skin deterioration, by stimulating natural dermal repair, another leading product in its pipeline is ICX-TRC, an injectable therapy aimed at regenerating hair follicles, offering a novel, biological solution to hair loss that moves beyond traditional cosmetic treatments, with headquarters in Manchester and GMP-compliant manufacturing facilities, Intercytex is equipped to support clinical-grade cell processing and scalable product development, backed by a strong intellectual property portfolio of over 100 patents, the company has raised more than $20 million in funding through seed rounds, venture capital, and a successful IPO, its partnerships with academic institutions and research organizations further strengthen its research and development capabilities, particularly in areas such as stem cell science and wound healing, Intercytex remains committed to transforming the field of regenerative medicine by offering therapies that don’t just manage symptoms, but actually stimulate the body’s own ability to heal, its vision is to create effective, scalable, and accessible treatments for skin damage, scarring, and hair loss, redefining how these conditions are treated through the application of advanced biomedical science and cell therapy innovation.
Keywords and Tags: regenerative medicine, cell therapy, hair regeneration, skin regeneration, wound healing, tissue engineering, dermal fibroblasts, epidermolysis bullosa treatment, burn scar repair, hair loss therapy, living cell therapy, injectable cell therapy, hair follicle regeneration, GMP manufacturing, clinical-stage biotech, dermatology innovation, stem cells, biomedical innovation, health technology, regenerativemedicine, celltherapy, hairregeneration, skinrepair, woundhealing, biotechinnovation, tissueengineering, stemcells, clinicaltrials, dermatology, hairlosstreatment, aestheticmedicine, biomedicalscience, medicalinnovation, healthtech.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2000
- Headquarters
- Manchester, United Kingdom
- Listing
- IPO 2006
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Dermatology, Spinout, Cell Therapy, DT and LS, uk is8 life sciences, UKSU, science-based
- Client focus
- b2c
- Investment activity
- 1 company, latest Dec 2008
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Sep 2008 | $3.6M | — | Undisclosed | ↗ |
| IPO✓Exit | Feb 2006 | $20M | $79M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Intercytex is 160 monthly website visits, down 42.9% over the last three months. Intercytex's team grew 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
- ABAvlar BioVentures
NIF Ventures
Scottish Equity Partners
3i Group
Excalibur Fund Managers
Other known investors2 additional known investors
University College LondonOmega Funds
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intercytex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intercytex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







